Cancer: Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance

Science Translational Medicine

Volumn 4, Issue 120, 2012, Pages

  Lovly, Christine M ^a   Pao, William ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANAPLASTIC LYMPHOMA KINASE GENE; CANCER RESISTANCE; COPY NUMBER VARIATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REARRANGEMENT; HUMAN; KIT GENE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NEUROBLASTOMA; NONHUMAN; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME; TUMOR GENE; GENETICS; LUNG TUMOR; METABOLISM; NOTE;

HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84857027931     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003728     Document Type: Review

References (31)

1. W. Pao, J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774 (2010).
2. R. Katayama, A. T. Shaw, T. M. Khan, M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. T. Yeo, C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate, J. A. Engelman, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 3, 120ra17 (2012).
3. S. C. Bresler, A. C. Wood, E. A. Haglund, J. Courtright, L. T. Belcastro, J. S. Plegaria, K. Cole, Y. Toporovskaya, H. Zhao, E. L. Carpenter, J. G. Christensen, J. M. Maris, M. A. Lemmon, Y. P. Mossé, Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114 (2011).
4. T. Iwahara, J. Fujimoto, D. Wen, R. Cupples, N. Bucay, T. Arakawa, S. Mori, B. Ratzkin, T. Yamamoto, Molecular characterization of ALK, A receptor tyrosine kinase expressed specifi cally in the nervous system. Oncogene 14, 439-449 (1997).
5. S. W. Morris, M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro, D. L. Saltman, A. T. Look, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
6. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano, Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 448, 561-566 (2007).
7. B. C. Gleason, J. L. Hornick, Infl ammatory myofi broblastic tumours: Where are we now? J. Clin. Pathol. 61, 428-437 (2008).
8. E. Lin, L. Li, Y. Guan, R. Soriano, C. S. Rivers, S. Mohan, A. Pandita, J. Tang, Z. Modrusan, Exon array profi ling detects EML4-ALK fusion in breast, colorectal, and nonsmall cell lung cancers. Mol. Cancer Res. 7, 1466-1476 (2009).
9. E. Sugawara, Y. Togashi, N. Kuroda, S. Sakata, S. Hatano, R. Asaka, T. Yuasa, J. Yonese, M. Kitagawa, H. Mano, Y. Ishikawa, K. Takeuchi, Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibodyenhanced polymer method. Cancer (2012).
10. Y. L. Choi, K. Takeuchi, M. Soda, K. Inamura, Y. Togashi, S. Hatano, M. Enomoto, T. Hamada, H. Haruta, H. Watanabe, K. Kurashina, H. Hatanaka, T. Ueno, S. Takada, Y. Yamashita, Y. Sugiyama, Y. Ishikawa, H. Mano, Identifi cation of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68, 4971-4976 (2008).
11. Y. Chen, J. Takita, Y. L. Choi, M. Kato, M. Ohira, M. Sanada, L. Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa, Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
12. Y. P. Mossé, M. Laudenslager, L. Longo, K. A. Cole, A. Wood, E. F. Attiyeh, M. J. Laquaglia, R. Sennett, J. E. Lynch, P. Perri, G. Laureys, F. Speleman, C. Kim, C. Hou, H. Hakonarson, A. Torkamani, N. J. Schork, G. M. Brodeur, G. P. Tonini, E. Rappaport, M. Devoto, J. M. Maris, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
13. I. Janoueix-Lerosey, D. Lequin, L. Brugières, A. Ribeiro, L. de Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron, D. Valteau-Couanet, T. Frebourg, J. Michon, S. Lyonnet, J. Amiel, O. Delattre, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
14. R. E. George, T. Sanda, M. Hanna, S. Fröhling, W. Luther, 2nd, J. Zhang, Y. Ahn, W. Zhou, W. B. London, P. McGrady, L. Xue, S. Zozulya, V. E. Gregor, T. R. Webb, N. S. Gray, D. G. Gilliland, L. Diller, H. Greulich, S. W. Morris, M. Meyerson, A. T. Look, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
15. A. K. Murugan, M. Xing, Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411 (2011).
16. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
17. F. A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes, S. Coughlin, Y. Kim, J. Berille, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103 (2000).
18. C. Gambacorti-Passerini, C. Messa, E. M. Pogliani, Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775-776 (2011).
19. J. E. Butrynski, D. R. D'Adamo, J. L. Hornick, P. Dal Cin, C. R. Antonescu, S. C. Jhanwar, M. Ladanyi, M. Capelletti, S. J. Rodig, N. Ramaiya, E. L. Kwak, J. W. Clark, K. D. Wilner, J. G. Christensen, P. A. Jänne, R. G. Maki, G. D. Demetri, G. I. Shapiro, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
20. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
21. N. P. Shah, J. M. Nicoll, B. Nagar, M. E. Gorre, R. L. Paquette, J. Kuriyan, C. L. Sawyers, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
22. H. Daub, K. Specht, A. Ullrich, Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001-1010 (2004).
23. Y. L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. ManoALK Lung Cancer Study Group, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
24. R. C. Doebele, A. B. Pilling, D. Aisner, T. G. Kutateladze, A. T. Le, A. J. Weickhardt, K. L. Kondo, D. J. Linderman, L. E. Heasley, W. A. Franklin, M. Varella-Garcia, D. R. Camidge, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. (2012). 10.1158/1078-0432.CCR-11-2906
25. R. Katayama, T. M. Khan, C. Benes, E. Lifshits, H. Ebi, V. M. Rivera, W. C. Shakespeare, A. J. Iafrate, J. A. Engelman, A. T. Shaw, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. U.S.A. 108, 7535-7540 (2011).
26. T. Sasaki, J. Koivunen, A. Ogino, M. Yanagita, S. Nikiforow, W. Zheng, C. Lathan, J. P. Marcoux, J. Du, K. Okuda, M. Capelletti, T. Shimamura, D. Ercan, M. Stumpfova, Y. Xiao, S. Weremowicz, M. Butaney, S. Heon, K. Wilner, J. G. Christensen, M. J. Eck, K. K. Wong, N. Lindeman, N. S. Gray, S. J. Rodig, P. A. Jänne, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060 (2011).
27. T. Sasaki, K. Okuda, W. Zheng, J. Butrynski, M. Capelletti, L. Wang, N. S. Gray, K. Wilner, J. G. Christensen, G. Demetri, G. I. Shapiro, S. J. Rodig, M. J. Eck, P. A. Jänne, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038-10043 (2010).
28. J. M. Heuckmann, M. Hölzel, M. L. Sos, S. Heynck, H. Balke-Want, M. Koker, M. Peifer, J. Weiss, C. M. Lovly, C. Grotter, D. Rauh, W. Pao, R. K. Thomas, ALK mutations conferring diff erential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 17, 7394-7401 (2011).
29. C. M. Lovly, J. M. Heuckmann, E. de Stanchina, H. Chen, R. K. Thomas, C. Liang, W. Pao, Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 71, 4920-4931 (2011).
30. L. V. Sequist, S. Gettinger, N. N. Senzer, R. G. Martins, P. A. Janne, R. Lilenbaum, J. E. Gray, A. J. Iafrate, R. Katayama, N. Hafeez, J. Sweeney, J. R. Walker, C. Fritz, R. W. Ross, D. Grayzel, J. A. Engelman, D. R. Borger, G. Paez, R. Natale, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defi ned non-small-cell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
31. L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).